IQV vs VEEV
IQV: IQVIA is a global leader in clinical research and healthcare data analytics that powers the development and commercialization of life-saving medical treatments. VEEV: Veeva provides the essential industry-cloud infrastructure that powers global life sciences companies throughout the entire drug development and commercialization lifecycle.
Side-by-side fundamentals
| Metric | IQV | VEEV | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $258.88 | $284.84 | |
| Market cap | $43.2B | $46.1B | |
| P/E as of 2026-10-08 | 32.10 | 50.39 | IQV lower |
| PEG | 2.90 | 2.30 | VEEV lower |
| Net margin | +8.3% | +28.4% | VEEV higher |
| Gross margin FY2026, SEC XBRL | n/a | +75.5% | |
| Operating margin | +13.4% | +28.7% | VEEV higher |
| ROE | +20.5% | +12.6% | IQV higher |
| ROA | +4.5% | +10.1% | VEEV higher |
| Debt / equity as of 2026-09-02 | 2.59 | 0.00 | VEEV lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.2% | +16.3% | VEEV higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +14.0% | VEEV higher |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | IQV higher |
| Beta as of 2026-09-02 | 0.97 | 0.67 | |
| 1-year return as of 2026-10-08 close | +29.1% | -5.6% | IQV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.